Mixed neuroendocrine-non-neuroendocrine neoplasms of the digestive system: A mini-review.
Mixed adenoneuorendocrine carcinoma
Mixed neuroendocrine neoplasms
Mixed neuroendocrine non-neuroendocrine neoplasms
Neuroendocrine
Non-neuroendocrine
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
21 May 2022
21 May 2022
Historique:
received:
09
11
2021
revised:
25
03
2022
accepted:
28
04
2022
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
ppublish
Résumé
Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) are rare mixed tumors containing both neuroendocrine (NE) and non-NE components. Each component must occupy at least 30% of the tumor volume by definition. Recent molecular evidence suggests MiNENs are clonal neoplasms and potentially harbor targetable mutations similar to conventional carcinomas. There have been multiple changes in the nomenclature and classification of MiNENs which has created some confusion among pathologists on how to integrate the contributions of each component in a MiNEN, an issue which in turn has resulted in confusion in communication with front-line treating oncologists. This mini review summarizes our current understanding of MiNENs and outline diagnosis, prognosis, and management of these neoplasms. The authors emphasize the importance of treating the most aggressive component of the tumor regardless of its percentage volume.
Identifiants
pubmed: 35664032
doi: 10.3748/wjg.v28.i19.2076
pmc: PMC9134131
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2076-2087Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: JL has received consulting fees from Taiho, Ipsen, Novartis, Amgen, Eisai, and Bayer; research funding from Ipsen Biopharmaceuticals, Amgen, and Foundation Medicine.
Références
Cancer Cytopathol. 2016 Dec;124(12):871-884
pubmed: 27529763
Mod Pathol. 2020 Dec;33(12):2602-2613
pubmed: 32461621
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Dis Colon Rectum. 2016 Dec;59(12):1160-1167
pubmed: 27824701
Hum Pathol. 2018 Mar;73:16-25
pubmed: 28899736
Cancers (Basel). 2012 Jan 16;4(1):11-30
pubmed: 24213223
Cancer Med. 2021 Jul;10(14):4855-4863
pubmed: 34109756
J Clin Med. 2020 Jan 19;9(1):
pubmed: 31963850
Endocr Pathol. 2016 Dec;27(4):284-311
pubmed: 27169712
Virchows Arch. 2018 Oct;473(4):435-441
pubmed: 29721608
Oncol Res Treat. 2019;42(3):123-127
pubmed: 30799422
Am J Surg Pathol. 2006 Aug;30(8):945-53
pubmed: 16861964
Cancers (Basel). 2021 Oct 12;13(20):
pubmed: 34680258
Oncotarget. 2017 Jun 27;8(41):69610-69621
pubmed: 29050228
JAMA Netw Open. 2021 Jul 1;4(7):e2114180
pubmed: 34313744
Digestion. 1994;55 Suppl 3:11-23
pubmed: 7698533
Eur J Cancer. 2014 Nov;50(16):2802-9
pubmed: 25201164
Am J Surg Pathol. 2018 Nov;42(11):1503-1512
pubmed: 30001239
Hum Pathol. 2016 Mar;49:124-34
pubmed: 26826419
Endocr Pathol. 2021 Jun;32(2):245-257
pubmed: 33786701
J Gastrointest Cancer. 2020 Mar;51(1):102-108
pubmed: 30784017
Anticancer Res. 2014 Oct;34(10):5517-21
pubmed: 25275049
Cancer Treat Rev. 2017 May;56:28-35
pubmed: 28456055
Am J Surg Pathol. 1987;11 Suppl 1:71-86
pubmed: 3544888
Mod Pathol. 2017 Apr;30(4):610-619
pubmed: 28059096
Eur J Surg Oncol. 2021 Feb;47(2):323-330
pubmed: 32907775
J Neuroendocrinol. 2021 May;33(5):e12967
pubmed: 33769624
Virchows Arch. 2006 Oct;449(4):395-401
pubmed: 16967267
Pathology. 2019 Jun;51(4):369-374
pubmed: 31040050
Diagn Pathol. 2019 May 10;14(1):38
pubmed: 31077220
World J Gastroenterol. 2019 Oct 21;25(39):5991-6005
pubmed: 31660035
Histopathology. 2020 Nov;77(5):700-717
pubmed: 32538468
Neuroendocrinology. 2017;105(4):412-425
pubmed: 28803232
Adv Anat Pathol. 2019 Mar;26(2):75-83
pubmed: 30601149
Lab Invest. 2003 Jul;83(7):963-71
pubmed: 12861036